600 560

Cited 0 times in

Helicobacter pylori 일,이차 제균요법 실패 후 Moxifloxacin 포함 삼제병합요법 시도

DC Field Value Language
dc.contributor.author천재희-
dc.date.accessioned2015-08-26T16:40:10Z-
dc.date.available2015-08-26T16:40:10Z-
dc.date.issued2005-
dc.identifier.issn1598-9992-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/114880-
dc.description.abstractBackground/Aims: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. Methods: The subjects consisted of 201 patients nfected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. Results:The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth riple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). Conclusions: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.-
dc.description.statementOfResponsibilityopen-
dc.format.extent111~117-
dc.languageKorean Journal of Gastroenterology-
dc.publisherKorean Journal of Gastroenterology-
dc.relation.isPartOfKorean Journal of Gastroenterology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHHelicobacter pylori-
dc.subject.MESHSecond-line therapy-
dc.subject.MESHRescue therapy-
dc.subject.MESHMoxifloxacin-
dc.titleHelicobacter pylori 일,이차 제균요법 실패 후 Moxifloxacin 포함 삼제병합요법 시도-
dc.title.alternativeTrial of Moxifloxacin-containing Triple Therapy after Initial and Second-line Treatment Failures for Helicobacter pylori Infection-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthor천재희-
dc.contributor.googleauthor김나영-
dc.contributor.googleauthor송인성-
dc.contributor.googleauthor정현채-
dc.contributor.googleauthor서승오-
dc.contributor.googleauthor김정목-
dc.contributor.googleauthor박영수-
dc.contributor.googleauthor황진혁-
dc.contributor.googleauthor김진욱-
dc.contributor.googleauthor이동호-
dc.identifier.doiOAK-2005-02088-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04030-
dc.relation.journalcodeJ02015-
dc.identifier.eissn2233-6869-
dc.subject.keywordHelicobacter pylori-
dc.subject.keywordSecond-line therapy-
dc.subject.keywordRescue therapy-
dc.subject.keywordMoxifloxacin-
dc.contributor.alternativeNameCheon, Jae Hee-
dc.contributor.affiliatedAuthorCheon, Jae Hee-
dc.rights.accessRightsfree-
dc.citation.volume45-
dc.citation.number2-
dc.citation.startPage111-
dc.citation.endPage117-
dc.identifier.bibliographicCitationKorean Journal of Gastroenterology, Vol.45(2) : 111-117, 2005-
dc.identifier.rimsid39284-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.